but thought it might be helpful to highlight one phrase from the recently announced Triolex trial:

Given the observed activity of HE3286 in reducing insulin resistance in both impaired glucose intolerant subjects and type 2 diabetic patients, it is necessary to evaluate the physiological site of action (i.e. liver vs. skeletal muscle) of HE3286 in order to further understand the mechanism of action and to design future clinical trials.

To design future trials. what do you need for future trials (plural!!)?
1. money
2. results that look promising.
nuff said.